FTD/TPI effective and well tolerated in elderly patients with advanced colorectal cancer

Key clinical point: Trifluridine/tipiracil (FTD/TPI) was effective and well tolerated in elderly patients with advanced colorectal cancer.

Major finding: Mean progression-free survival (PFS) was 2.3 (95% confidence interval [CI], 1.9-4.3) months, with the study meeting its predefined primary endpoint of PFS with the lower limit of 95% CI being more than 1.0 month. The median overall survival was 5.7 (95% CI, 3.7-8.9) months. Grade 3 or 4 adverse events were observed in 80% of patients, the most common being neutropenia, anemia, and anorexia.

Study details: Findings are from a single-arm phase 2 trial of 30 elderly patients aged 65 years or older who had fluoropyrimidine-refractory advanced colorectal cancer and received FTD/TPI.

Disclosures: This study was supported by the Tohoku Clinical Oncology Research and Education Society. M Takahashi and C Ishioka reported receiving lecture fees and/or funding from various sources. The remaining authors declared no conflicts of interest.

Source: Takahashi M et al. Cancer Chemother Pharmacol. 2021 May 24. doi: 10.1007/s00280-021-04277-3.

Key clinical point: Trifluridine/tipiracil (FTD/TPI) was effective and well tolerated in elderly patients with advanced colorectal cancer.

Major finding: Mean progression-free survival (PFS) was 2.3 (95% confidence interval [CI], 1.9-4.3) months, with the study meeting its predefined primary endpoint of PFS with the lower limit of 95% CI being more than 1.0 month. The median overall survival was 5.7 (95% CI, 3.7-8.9) months. Grade 3 or 4 adverse events were observed in 80% of patients, the most common being neutropenia, anemia, and anorexia.

Study details: Findings are from a single-arm phase 2 trial of 30 elderly patients aged 65 years or older who had fluoropyrimidine-refractory advanced colorectal cancer and received FTD/TPI.

Disclosures: This study was supported by the Tohoku Clinical Oncology Research and Education Society. M Takahashi and C Ishioka reported receiving lecture fees and/or funding from various sources. The remaining authors declared no conflicts of interest.

Source: Takahashi M et al. Cancer Chemother Pharmacol. 2021 May 24. doi: 10.1007/s00280-021-04277-3.

Key clinical point: Trifluridine/tipiracil (FTD/TPI) was effective and well tolerated in elderly patients with advanced colorectal cancer.

Major finding: Mean progression-free survival (PFS) was 2.3 (95% confidence interval [CI], 1.9-4.3) months, with the study meeting its predefined primary endpoint of PFS with the lower limit of 95% CI being more than 1.0 month. The median overall survival was 5.7 (95% CI, 3.7-8.9) months. Grade 3 or 4 adverse events were observed in 80% of patients, the most common being neutropenia, anemia, and anorexia.

Study details: Findings are from a single-arm phase 2 trial of 30 elderly patients aged 65 years or older who had fluoropyrimidine-refractory advanced colorectal cancer and received FTD/TPI.

Disclosures: This study was supported by the Tohoku Clinical Oncology Research and Education Society. M Takahashi and C Ishioka reported receiving lecture fees and/or funding from various sources. The remaining authors declared no conflicts of interest.

Source: Takahashi M et al. Cancer Chemother Pharmacol. 2021 May 24. doi: 10.1007/s00280-021-04277-3.